Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly ...

The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...

Eli Lilly LLY announced positive topline results from two phase III studies, QWINT-1 and QWINT-3, which evaluated efsitora ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Eli Lilly and Company has revealed positive topline results from the Phase III trials of efsitora alfa to treat adults with ...

The phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better ...

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.

Jaipur: The state health department has declared five medicine samples as substandard following tests and analysis.

A pair of late-stage trials found that Eli Lilly’s experimental once-weekly insulin can lower blood sugar as effectively as ...

Eli Lilly's efsitora alfa was noninferior to once-daily insulin in type 2 diabetes, but an increased hypoglycemia risk was seen in type 1 diabetes.

Abbott launched an over-the-counter continuous glucose monitoring system, Lingo, for adults not on insulin -- the second such ...

Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...